# US 2013/0261102 A1 · Heterocyclic compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261102 A1
- Document ID: US20130261102A1
- Status: Published application
- Kind: A1
- Application number: 13/699,611
- Filed: 2011-05-24
- Published: 2013-10-03
- Earliest claimed: 2010-05-24
- Assignees: Intellikine LLC
- Inventors: Pingda Ren; Yi Liu; Liansheng Li; Katrina Chan; Troy Edward Wilson; Simon Fraser Campbell
- Web page: https://patentgrep.com/patent/US20130261102A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

## Claims

### Claim 1

A compound of Formula I:
or its pharmaceutically acceptable salts thereof, wherein:
W1 is is N, NR3, or CR3; W2 is N, NR4, CR4, or C═O; W3 is N, NR5 or CR5; W4 is N or NR6, wherein no more than two N atoms and no more than two C═O groups are adjacent;
W5 is N or NR7;
W6 is N or CR8e;
Wa and Wb are independently N or CR9;
one of Wc and Wd is N, and the other is O, NR10, or S;
R1 and R2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
R3 and R4 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
or R3 and R4 taken together form a cyclic moiety;
R5, R6, R7 and R8 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
R9 is alkyl or halo; and
R10 is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 2 (depends on 1)

The compound of claim 1, wherein W2 is CR4.

### Claim 3 (depends on 1)

The compound of claim 1, wherein W3 is CR5.

### Claim 4 (depends on 1)

The compound of claim 1, wherein W4 is N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein W5 is N.

### Claim 6 (depends on 1)

The compound of claim 1, wherein W2 and W3 are CH.

### Claim 7 (depends on 1)

The compound of claim 1, wherein W6 is CR8.

### Claim 8 (depends on 1)

The compound of claim 1, wherein W1 is N.

### Claim 9 (depends on 1)

The compound of claim 1, wherein W1 is CR3.

### Claim 10 (depends on 1)

The compound of claim 1, wherein Wb is CR9.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Wb is N.

### Claim 12 (depends on 1)

The compound of claim 1, wherein Wa is CR9 and R9 is alkyl or hydrogen.

### Claim 13 (depends on 1)

The compound of claim 1, wherein Wa is CR9 and R9 is alkyl.

### Claim 14 (depends on 1)

The compound of claim 1, wherein Wa and Wb are CR9 and R9 is hydrogen.

### Claim 15 (depends on 1)

The compound of claim 1, wherein Wc is N and and Wd is O.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R2 is amino.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound has the Formula:

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound has the Formula:

### Claim 20 (depends on 18, 19)

The compound of claim 18 or 19, wherein Wc is N and and Wd is O.

### Claim 21 (depends on 18, 19)

The compound of claim 18 or 19, wherein W2 and W3 are CH.

### Claim 22 (depends on 18, 19)

The compound of claim 18 or 19, wherein R2 is amino.

### Claim 23 (depends on 18, 19)

The compound of claim 18 or 19, wherein R1 is H.

### Claim 24 (depends on 1, 18, 19)

The compound of claim 1, 18 or 19, wherein W2 is CR4 and R4 is alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R4 is aryl, heteroaryl, heterocycloalkyl, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 26 (depends on 24)

The compound of claim 24, wherein R4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 27 (depends on 24)

The compound of claim 24, wherein R4 is 5 or 6-membered heteroaryl.

### Claim 28 (depends on 24)

The compound of claim 24, wherein R4 is NR′R″ and R′ and R″ are taken together with nitrogen to form a 4-, 5-, or 6-membered heterocyclic moiety.

### Claim 29 (depends on 28)

The compound of claim 28, wherein the heterocyclic moiety is morpholine, piperazine, azetidine, pyrrolidine, or piperidine.

### Claim 30 (depends on 25)

The compound of claim 25, wherein R4 is further substituted with alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 31

A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase), comprising: contacting the PI3 kinase with an effective amount of a compound of any one of the preceding claims.

### Claim 32 (depends on 31)

The method of claim 31, wherein said step of contacting comprises contacting a cell that expresses said PI3 kinase.

### Claim 33 (depends on 31)

The method of claim 31, wherein the PI3 kinase is PI3 kinase alpha.

### Claim 34 (depends on 31)

The method of claim 31, comprising administering a second therapeutic agent to the cell.

### Claim 35 (depends on 31)

The method of claim 31, wherein the contacting step takes place in vivo.

### Claim 36 (depends on 31)

The method of claim 31, wherein the contacting step takes place in vitro.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of treating a condition associated with PI3 kinase, comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1-30.

### Claim 38 (depends on 37)

The method of claim 37, wherein the condition is selected from the group consisting of asthma, emphysema, bronchitis, psoriasis, allergy, anaphylaxis, rheumatoid arthritis, graft versus host disease, lupus erythematosus, psoriasis, restenosis, benign prostatic hypertrophy, diabetes, pancreatitis, proliferative glomerulonephritis, diabetes-induced renal disease, inflammatory bowel disease, atherosclerosis, eczema, scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
